IL288609B - Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog - Google Patents

Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog

Info

Publication number
IL288609B
IL288609B IL288609A IL28860921A IL288609B IL 288609 B IL288609 B IL 288609B IL 288609 A IL288609 A IL 288609A IL 28860921 A IL28860921 A IL 28860921A IL 288609 B IL288609 B IL 288609B
Authority
IL
Israel
Prior art keywords
rapalog
production
methods
synthetic nanocarriers
low hlb
Prior art date
Application number
IL288609A
Other languages
Hebrew (he)
Other versions
IL288609B2 (en
IL288609A (en
Original Assignee
Selecta Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selecta Biosciences Inc filed Critical Selecta Biosciences Inc
Publication of IL288609A publication Critical patent/IL288609A/en
Publication of IL288609B publication Critical patent/IL288609B/en
Publication of IL288609B2 publication Critical patent/IL288609B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cosmetics (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
IL288609A 2014-11-05 2021-12-02 Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog IL288609B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462075864P 2014-11-05 2014-11-05
US201462075866P 2014-11-05 2014-11-05
PCT/US2015/059349 WO2016073798A1 (en) 2014-11-05 2015-11-05 Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog

Publications (3)

Publication Number Publication Date
IL288609A IL288609A (en) 2022-02-01
IL288609B true IL288609B (en) 2022-10-01
IL288609B2 IL288609B2 (en) 2023-02-01

Family

ID=54697646

Family Applications (7)

Application Number Title Priority Date Filing Date
IL295292A IL295292B1 (en) 2014-11-05 2015-11-05 Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state
IL283699A IL283699B (en) 2014-11-05 2015-11-05 Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state
IL296246A IL296246A (en) 2014-11-05 2015-11-05 Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog
IL251622A IL251622B (en) 2014-11-05 2017-04-06 Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state
IL251620A IL251620B (en) 2014-11-05 2017-04-06 Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog
IL280518A IL280518B (en) 2014-11-05 2021-01-31 Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog
IL288609A IL288609B2 (en) 2014-11-05 2021-12-02 Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog

Family Applications Before (6)

Application Number Title Priority Date Filing Date
IL295292A IL295292B1 (en) 2014-11-05 2015-11-05 Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state
IL283699A IL283699B (en) 2014-11-05 2015-11-05 Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state
IL296246A IL296246A (en) 2014-11-05 2015-11-05 Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog
IL251622A IL251622B (en) 2014-11-05 2017-04-06 Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state
IL251620A IL251620B (en) 2014-11-05 2017-04-06 Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog
IL280518A IL280518B (en) 2014-11-05 2021-01-31 Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog

Country Status (23)

Country Link
US (2) US20160128986A1 (en)
EP (6) EP3215192B1 (en)
JP (5) JP7218089B2 (en)
KR (2) KR102601922B1 (en)
CN (5) CN115212186A (en)
AU (4) AU2015342968B2 (en)
BR (3) BR122021025344B1 (en)
CA (2) CA2966852C (en)
CY (1) CY1124418T1 (en)
DK (4) DK3906918T3 (en)
EA (2) EA201790977A1 (en)
ES (4) ES2977158T3 (en)
FI (2) FI3834823T3 (en)
HR (1) HRP20210098T1 (en)
HU (3) HUE053094T2 (en)
IL (7) IL295292B1 (en)
LT (1) LT3215133T (en)
MX (4) MX2017005904A (en)
PL (1) PL3215133T3 (en)
PT (1) PT3215133T (en)
RS (1) RS61359B1 (en)
SI (1) SI3215133T1 (en)
WO (2) WO2016073798A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6297775B2 (en) 2009-05-27 2018-03-20 セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． Target-directed synthetic nanocarriers with pH-sensitive release of immunomodulators
BR112012029912A2 (en) 2010-05-26 2016-11-16 Selecta Biosciences Inc Synthetic Nanotransport Combination Vaccines
EP2640190A4 (en) 2010-11-05 2016-05-11 Selecta Biosciences Inc Modified nicotinic compounds and related methods
CA2834532A1 (en) 2011-04-29 2012-11-01 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses
MX2014001142A (en) 2011-07-29 2014-02-27 Selecta Biosciences Inc Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses.
US10357482B2 (en) 2013-05-03 2019-07-23 Selecta Biosciences, Inc. Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivity
WO2015025538A1 (en) * 2013-08-20 2015-02-26 サンノプコ株式会社 Additive for bioethanol fermentation process and method for producing bioethanol
KR20240123409A (en) 2014-09-07 2024-08-13 셀렉타 바이오사이언시즈, 인크. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
US10125378B2 (en) * 2015-02-17 2018-11-13 San Nopco Ltd. Additive for bioethanol fermentation process and method for producing bioethanol
US10973925B2 (en) * 2015-04-28 2021-04-13 University Of Central Florida Research Foundation Inc. Methods and compositions for theranostic nanoparticles
KR20220123332A (en) 2016-03-11 2022-09-06 셀렉타 바이오사이언시즈, 인크. Formulations and doses of pegylated uricase
KR102341902B1 (en) * 2016-09-09 2021-12-21 카오카부시키가이샤 Dicarboxylic acid crystal and method for producing same
EP3518956A1 (en) 2016-09-27 2019-08-07 Selecta Biosciences, Inc. Recombinant immunotoxins for use in the treatment of cancer
US20180193482A1 (en) 2017-01-07 2018-07-12 Selecta Biosciences, Inc. Patterned dosing of immunosuppressants coupled to synthetic nanocarriers
AU2018236123B2 (en) 2017-03-11 2024-04-18 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
CN111542336A (en) 2017-10-13 2020-08-14 西莱克塔生物科技公司 Methods and compositions for attenuating antiviral transfer vector IGM response
JP2022531201A (en) 2019-04-28 2022-07-06 セレクタ バイオサイエンシーズ インコーポレーテッド Methods for the treatment of subjects with existing immunity to the virus-introduced vector
JP2022534741A (en) 2019-05-28 2022-08-03 セレクタ バイオサイエンシーズ インコーポレーテッド Methods and compositions for attenuated antiviral transduction vector immune response
WO2020247625A1 (en) 2019-06-04 2020-12-10 Selecta Biosciences, Inc. Formulations and doses of pegylated uricase
MX2022004759A (en) 2019-10-21 2022-08-19 Selecta Biosciences Inc Methods and compositions for treating liver diseases and disorders.
WO2021092354A1 (en) 2019-11-08 2021-05-14 Selecta Biosciences, Inc. Formulations and doses of pegylated uricase
US20210290601A1 (en) 2020-02-26 2021-09-23 Selecta Biosciences, Inc. Methods and compositions using synthetic nanocarriers comprising immunosuppressant
US20210308058A1 (en) * 2020-03-11 2021-10-07 Selecta Biosciences, Inc. Methods and compositions related to synthetic nanocarriers
KR20230002613A (en) 2020-04-14 2023-01-05 셀렉타 바이오사이언시즈, 인크. Methods and compositions for inducing autophagy
AU2021373792A1 (en) 2020-11-04 2023-06-08 Selecta Biosciences, Inc. Compositions for reducing immune responses against immunoglobulin proteases
AU2022206197A1 (en) 2021-01-05 2023-07-13 Selecta Biosciences, Inc. Viral vector dosing protocols
KR102304785B1 (en) 2021-03-26 2021-09-24 (주)진성티앤피 Method for manufacturing parts of precision optical devices
BR112023020597A2 (en) 2021-04-09 2023-12-12 Selecta Biosciences Inc SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT IN COMBINATION WITH HIGH AFFINITY IL-2 RECEPTOR AGONITS TO INCREASE IMMUNE TOLERANCE
US20240189447A1 (en) 2021-04-16 2024-06-13 Asklepios Biopharmaceutical, Inc. Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
US20230140196A1 (en) 2021-10-12 2023-05-04 Selecta Biosciences, Inc. Viral vector dosing protocols
CA3237037A1 (en) 2021-11-14 2023-05-19 Cartesian Therapeutics, Inc. Multiple dosing with viral vectors
WO2023133319A1 (en) 2022-01-10 2023-07-13 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
US20230322884A1 (en) 2022-03-09 2023-10-12 Selecta Biosciences, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
WO2023196566A1 (en) 2022-04-08 2023-10-12 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
US20240148841A1 (en) 2022-08-11 2024-05-09 Selecta Biosciences Inc. Compositions and methods related to immunoglobulin proteases and fusions thereof
WO2024107889A1 (en) 2022-11-15 2024-05-23 Selecta Biosciences, Inc. Compositions and methods for treating primary biliary cholangitis

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946929A (en) 1983-03-22 1990-08-07 Massachusetts Institute Of Technology Bioerodible articles useful as implants and prostheses having predictable degradation rates
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4806621A (en) 1986-01-21 1989-02-21 Massachusetts Institute Of Technology Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article
CA1340581C (en) 1986-11-20 1999-06-08 Joseph P. Vacanti Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices
US5736372A (en) 1986-11-20 1998-04-07 Massachusetts Institute Of Technology Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure
US5804178A (en) 1986-11-20 1998-09-08 Massachusetts Institute Of Technology Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue
US5019379A (en) 1987-07-31 1991-05-28 Massachusetts Institute Of Technology Unsaturated polyanhydrides
US5010167A (en) 1989-03-31 1991-04-23 Massachusetts Institute Of Technology Poly(amide-and imide-co-anhydride) for biological application
US5399665A (en) 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
US5514378A (en) 1993-02-01 1996-05-07 Massachusetts Institute Of Technology Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5716404A (en) 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US6123727A (en) 1995-05-01 2000-09-26 Massachusetts Institute Of Technology Tissue engineered tendons and ligaments
US6095148A (en) 1995-11-03 2000-08-01 Children's Medical Center Corporation Neuronal stimulation using electrically conducting polymers
US5902599A (en) 1996-02-20 1999-05-11 Massachusetts Institute Of Technology Biodegradable polymer networks for use in orthopedic and dental applications
AU735648B2 (en) 1996-07-12 2001-07-12 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US7288266B2 (en) 1996-08-19 2007-10-30 United States Of America As Represented By The Secretary, Department Of Health And Human Services Liposome complexes for increased systemic delivery
US5837752A (en) 1997-07-17 1998-11-17 Massachusetts Institute Of Technology Semi-interpenetrating polymer networks
US6187335B1 (en) 1997-12-31 2001-02-13 Orasomal Technologies, Inc. Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom
US6686446B2 (en) 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6506577B1 (en) 1998-03-19 2003-01-14 The Regents Of The University Of California Synthesis and crosslinking of catechol containing copolypeptides
US6632922B1 (en) 1998-03-19 2003-10-14 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
EP1100464A1 (en) 1998-07-31 2001-05-23 Korea Institute Of Science And Technology Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier
CA2731995C (en) * 1998-09-01 2013-05-28 Merrion Research Iii Limited Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor
CN1406140A (en) 2000-02-28 2003-03-26 吉倪塞思公司 Nano capsule encapsulation system and method
US6818732B2 (en) 2001-08-30 2004-11-16 The Regents Of The University Of California Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
WO2004017943A2 (en) 2002-08-23 2004-03-04 Medigene Oncology Gmbh Non-vesicular cationic lipid formulations
CN1886100A (en) * 2003-11-14 2006-12-27 阿尔萨公司 Surfactant-based gel as an injectable, sustained drug delivery vehicle
US20050260260A1 (en) 2004-05-19 2005-11-24 Edward Kisak Liposome compositions for the delivery of macromolecules
EP1928435B8 (en) * 2005-08-31 2019-03-20 Abraxis BioScience, LLC Compositions of poorly water soluble drugs with increased stability and methods for preparation thereof
US8414910B2 (en) * 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
EP2620157A3 (en) 2007-10-12 2013-10-16 Massachusetts Institute of Technology Vaccine nanotechnology
PT2774608T (en) * 2008-06-16 2020-01-17 Pfizer Drug loaded polymeric nanoparticles and methods of making and using same
US8613951B2 (en) * 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
CN101676291B (en) 2008-09-18 2012-05-09 上海海和药物研究开发有限公司 Rapamycin carbonate analog, pharmaceutical composition thereof, and preparation method and uses thereof
WO2010075072A2 (en) * 2008-12-15 2010-07-01 Bind Biosciences Long circulating nanoparticles for sustained release of therapeutic agents
KR101267813B1 (en) * 2009-12-30 2013-06-04 주식회사 삼양바이오팜 An injectable composition comprising polymeric nanoparticles containing rapamycin with an improved water solubility and a method for preparing the same, and an anticancer composition comprising the same for a combination therapy with radiation
US9757456B2 (en) * 2010-09-14 2017-09-12 Nanologica Ab Super-saturating delivery vehicles for poorly water-soluble pharmaceutical and cosmetic active ingredients and suppression of crystallization of pharmaceutical active ingredients
WO2012059936A1 (en) * 2010-11-03 2012-05-10 Padma Venkitachalam Devarajan Pharmaceutical compositions for colloidal drug delivery
CA2834532A1 (en) * 2011-04-29 2012-11-01 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses
CN102793674B (en) * 2011-05-26 2014-11-26 澳门科技大学 Triptolide solid lipid nanoparticle as well as preparation method and application thereof
WO2013056132A2 (en) 2011-10-14 2013-04-18 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
CN102871966B (en) * 2012-10-19 2013-11-20 东南大学 Nano drug carrier particles for improving bioavailability of rapamycin and preparation method thereof

Also Published As

Publication number Publication date
FI3906918T3 (en) 2024-04-04
WO2016073799A9 (en) 2016-12-08
KR102656139B1 (en) 2024-04-11
EP4356910A2 (en) 2024-04-24
CN113244191A (en) 2021-08-13
FI3834823T3 (en) 2024-04-02
IL283699A (en) 2021-07-29
PT3215133T (en) 2021-01-29
JP6912377B2 (en) 2021-08-04
EP3906918A1 (en) 2021-11-10
AU2015342968B2 (en) 2021-05-27
JP2022173236A (en) 2022-11-18
WO2016073798A1 (en) 2016-05-12
EP4360633A3 (en) 2024-05-22
DK3834823T3 (en) 2024-04-08
AU2021209202B2 (en) 2023-11-30
RS61359B1 (en) 2021-02-26
KR20170081659A (en) 2017-07-12
IL296246A (en) 2022-11-01
US20160128987A1 (en) 2016-05-12
DK3906918T3 (en) 2024-04-08
CN115212187A (en) 2022-10-21
CA2966850C (en) 2024-03-26
HRP20210098T1 (en) 2021-03-05
BR112017008720A2 (en) 2017-12-19
CA2966850A1 (en) 2016-05-12
EP3215133B1 (en) 2020-10-28
PL3215133T3 (en) 2021-06-14
KR20170081660A (en) 2017-07-12
HUE066099T2 (en) 2024-07-28
BR122021025344B1 (en) 2024-02-20
SI3215133T1 (en) 2021-07-30
EA201790978A1 (en) 2017-09-29
IL295292A (en) 2022-10-01
EP3215192B1 (en) 2021-02-17
EP3834823A1 (en) 2021-06-16
JP7218089B2 (en) 2023-02-06
EP3906918B1 (en) 2024-01-03
ES2865375T3 (en) 2021-10-15
CN107072965B (en) 2021-05-11
ES2977158T3 (en) 2024-08-20
MX2021012273A (en) 2021-11-12
WO2016073799A1 (en) 2016-05-12
AU2021209204A1 (en) 2021-08-19
JP2023169893A (en) 2023-11-30
JP2021143180A (en) 2021-09-24
EP4360633A2 (en) 2024-05-01
DK3215133T3 (en) 2021-02-01
HUE054894T2 (en) 2021-10-28
CN107072964A (en) 2017-08-18
JP2017533243A (en) 2017-11-09
BR112017008499B1 (en) 2023-10-03
AU2015342969B2 (en) 2021-05-27
ES2846809T3 (en) 2021-07-29
AU2015342969A1 (en) 2017-04-27
BR112017008499A2 (en) 2017-12-26
CA2966852C (en) 2024-01-02
MX2021006698A (en) 2021-07-07
IL283699B (en) 2022-09-01
CN107072965A (en) 2017-08-18
KR102601922B1 (en) 2023-11-15
IL295292B1 (en) 2024-06-01
IL251620B (en) 2021-02-28
EA201790977A1 (en) 2017-10-31
EP3215192A4 (en) 2018-05-02
EP3215133A1 (en) 2017-09-13
US20160128986A1 (en) 2016-05-12
AU2021209202A1 (en) 2021-08-19
IL251622A0 (en) 2017-06-29
CN115212186A (en) 2022-10-21
EP4356910A3 (en) 2024-05-22
JP2017537081A (en) 2017-12-14
IL251622B (en) 2021-06-30
LT3215133T (en) 2021-02-25
MX2017005903A (en) 2017-06-27
EP3834823B1 (en) 2024-01-03
MX2017005904A (en) 2017-06-27
IL280518A (en) 2021-03-01
IL251620A0 (en) 2017-06-29
DK3215192T3 (en) 2021-05-03
IL288609B2 (en) 2023-02-01
IL280518B (en) 2022-01-01
ES2977259T3 (en) 2024-08-21
HUE053094T2 (en) 2021-06-28
CA2966852A1 (en) 2016-05-12
EP3215192A1 (en) 2017-09-13
CY1124418T1 (en) 2022-07-22
AU2015342968A1 (en) 2017-04-27
IL288609A (en) 2022-02-01

Similar Documents

Publication Publication Date Title
IL288609B (en) Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog
IL249011A0 (en) Methods and compositions relating to exosomes
GB201401066D0 (en) Improvements in and relating to screens
GB201415632D0 (en) Improvements in and relating to displays
EP2951217A4 (en) Surfactants and methods of making and using same
ZA201804773B (en) Use of emulsifier in collector composition
IL245529A0 (en) Rapidly disintegrating formulations and methods of use
PL3229591T3 (en) Sugar surfactants and use thereof in agrochemical compositions
GB201400431D0 (en) Phospholipid compositions and their preparation
IL251957A0 (en) Il-12 compositions and methods of use in hematopoietic recovery
PT3148517T (en) Compositions and methods to promote bone formation
GB201421000D0 (en) Improvements in and relating to displays
GB201401340D0 (en) Improvements in and relating to zipwire trolleys
HK1243404A1 (en) Tryptamide compositions and methods of use
GB201418071D0 (en) Improvement in or relation to fishing
GB201518802D0 (en) Improvements in and relating to nozzles
GB2517846B (en) Improvements in and relating to loudspeakers
GB201514431D0 (en) Improvements in and relating to materials
GB2530075B (en) Improvements in and relating to eyewashing
GB201417432D0 (en) Improvements in and relating to pipe-breaking
GB201417404D0 (en) Improvements in and relating to radar
GB201412345D0 (en) Improvements in and relating to devices
GB201410254D0 (en) Improvements in and relating to kettles
GB201404525D0 (en) Improvements in and relating to displays
GB201404526D0 (en) Improvements in and relating to displays